The US FDA has approved both gefitinib and erlotinib as first‐line treatment for NSCLC with EGFR exon 19 deletion or exon 21 (L858R) mutations, based on the evidence that they can significantly improve median PFS and ORR, compared with chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.